A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant ARF876L nuclear import and function.

Zeyu WuKe WangZhenyu YangLaura E PascalJoel B NelsonKeita TakuboPeter WipfZhou Wang

Published in: The Prostate (2019)

JJ-450 inhibits enzalutamide-resistant ARF876L mutant nuclear translocation and function. Our findings suggest that JJ-450 and its analogs should be further developed to provide a potential new approach for the treatment of enzalutamide-resistant CRPC.

Keyphrases

prostate cancer
wild type